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Development of a vaccine against congenital cytomegalovirus (CMV) infection is a public health priority, but CMVs encode
immune evasion genes that complicate live virus vaccine design. To resolve this problem, this study employed guanosyl
phosphoribosyl transferase (gpt) mutagenesis to generate a recombinant guinea pig CMV (GPCMV) with a knockout of a viral
chemokine gene, GPCMV MIP (gp1). MIP deletion virus replicated with wild-type kinetics in cell culture but was attenuated in
nonpregnant guinea pigs, demonstrating reduced viremia and reduced inflammation and histopathology (compared to a control
virus with an intact GPCMV MIP gene) following footpad inoculation. In spite of attenuation, the vaccine was immunogenic,
eliciting antibody responses comparable to those observed in natural infection. To assess its protective potential as a vaccine,
either recombinant virus or placebo was used to immunize seronegative female guinea pigs. Dams were challenged in the early 3rd
trimester with salivary gland-adaptedGPCMV. Immunization protected against DNAemia (1/15 in vaccine group versus 12/13 in the
control group,𝑃 < 0.01).Mean birthweights were significantly higher in pups born to vaccinated dams compared to controls (98.7 g
versus 71.2 g, 𝑃 < 0.01). Vaccination reduced pupmortality, from 35/50 (70%) in controls to 8/52 (15%) in the immunization group.
Congenital GPCMV infection was also reduced, from 35/50 (70%) in controls to 9/52 (17%) in the vaccine group (𝑃 < 0.0001). We
conclude that deletion of an immunemodulation gene can attenuate the pathogenicity of GPCMVwhile resulting in a viral vaccine
that retains immunogenicity and demonstrates efficacy against congenital infection and disease.
1. Introduction
Human cytomegalovirus (HCMV) is themost common cause
of viral congenital infection in the developed world and is
estimated to complicate approximately 0.5–2%of pregnancies
in the United States and Europe. Congenital infections
can cause severe sequelae among neonates including sen-
sorineural hearing loss, cognitive impairments, and mental
retardation [1–3]. In the setting ofmaternal primary infection
or reinfection during pregnancy, HCMV can translocate the
placental barrier and can cause infection of the developing
fetus, with attendant morbidity and occasional mortality [4].
Unfortunately, animal models are of limited usefulness in the
study of antiviral and vaccine strategies against HCMV, due
to the extreme species specificity of CMVs. It is therefore
necessary to study species-specific CMVs in animal models
that mimic HCMV congenital infection, in order to evaluate
therapeutic and preventive strategies that may ultimately be
clinically useful. Among the CMVs of small mammals, the
GPCMV has the unique advantage of crossing the placenta,
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causing infection in utero [5, 6]. This feature of the biology
of GPCMV makes it ideal for vaccine studies, since congen-
itally infected pups, like newborn infants, have virus-related
morbidity and mortality.
All CMVs encode genes that confer immunomodulatory
functions that may impact the efficiency of infection, dissem-
ination, reactivation and persistence in the host (reviewed
in [7]). Such immune evasion genes include homologs of
chemokines (CKs), G protein-coupled receptors (GPCRs),
and modulators of antigen processing and presentation [8–
12]. In addition to contributing to modification of host
immune responses, some of these viral proteins may play
a role in promoting dissemination during acute infection.
GPCMV, similar to other CMVs, encodes a number of poten-
tial immunomodulatory gene products [13, 14]. The gp1 ORF
encodes one such gene product that has been characterized
in previous studies [13, 14]. The protein, GPCMV-MIP, is a
member of the CC family of CKs and is most closely related
to the macrophage inflammatory protein (MIP) 1𝛼 family.
Previous studies with a recombinant form of this protein
demonstrated that specific signaling could be mediated via
the hCCR1 receptor and that this interaction could be
blockedwith humanMIP 1𝛼 in competition experiments [14].
Moreover, migration assays revealed that GPCMV-MIP was
able to induce chemotaxis in transfected hCCR1-L1.2 cells.
Subsequent studies in a model of virus-induced labyrinthitis,
comparing a recombinant GPCMV deleted of the GPCMV
MIP gene with wild-type virus, indicated a potential role
for this CK in pathogenesis, insofar as the “knock-out”
virus demonstrated reduction both in the magnitude of
hearing loss and in cochlear inflammation, following direct
inoculation of the guinea pig cochlea via the round window
[15, 16]. Thus, deletion of this gene appears to substantively
attenuate the pathogenicity of the resulting recombinant virus
in vivo.
Both purified protein subunit vaccines and live, atten-
uated vaccines have been proposed as strategies to prevent
congenital CMV infection [17]. Significant concerns have
been raised, however, regarding the deployment of live,
attenuatedHCMVvaccines in clinical practice.These include
the concern that live virus vaccines might establish latency,
theoretically putting the vaccine recipient at risk to develop
as yet unproven long-term adverse consequences related
to HCMV infection, including autoimmune disease, malig-
nancy, and atherosclerosis [18]. In addition, any live virus
vaccine must in principle be sufficiently attenuated such that
it would not pose any untoward risks when administered to
vaccinees, including the setting of inadvertent administration
to a pregnant woman. A potential solution to the challenge
of developing a safe live-virus vaccine for HCMV is to use
recombinant technologies to engineer attenuated vaccines
that, by virtue of targeted removal of genes that contribute
to immune modulation and/or pathogenesis in vivo, could
in principle retain immunogenicity while avoiding potential
risks. This strategy has been successfully employed in the
murine CMV (MCMV) model, where deletions of large
segments of the viral genome encoding immune modulation
genes result in a virus with essentially complete attenuation
and an inability to establish latency, which nonetheless
retains immunogenicity and provides protective efficacy as a
vaccine [19–21]. However, a limitation of the MCMV model
is that it does not allow testing of vaccines for prevention
against congenital transmission, because of the inability of
MCMV to cross the mouse placenta [22]. Therefore, we
sought to test whether a live, attenuated GPCMV vaccine
when administrated before conception could engender an
immune response sufficient to protect against congenital
viral transmission in the guinea pig model. Specifically, these
studies were undertaken to test the hypothesis that a GPCMV
(gp1)MIP deletion virus would, though attenuated, retain the
ability to protect against congenital GPCMV infection and
disease when used as a preconception vaccine.
2. Materials and Methods
2.1. Cells and Viruses. GPCMV (strain 22122, ATCCVR682),
v545 [15, 16], and vAM403, an enhanced green-fluorescent-
protein-(eGFP-) tagged GPCMV [23], were propagated on
guinea pig fibroblast lung cells (GPL; ATCC CCL 158) in F-
12 medium supplemented with 10% fetal calf serum (FCS;
Gibco-BRl), 10,000 IU of penicillin/liter, 10mg of strepto-
mycin/liter (Gibco-BRL), and 7.5% NaHCO
3
(Gibco-BRL).
For generation of the GPCMV MIP “knock-out” virus,
guanosyl phosphoribosyl transferase (gpt) mutagenesis was
employed, as previously described [23]. A 2.3 kb EcoR I
fragment containing the GPCMV-MIP was subcloned into
pBluescript (+) from a plasmid containing the Hind III “D”
fragment, yielding plasmid pKTS 107. A 320 bp Stu I collapse,
deleting the GPCMVMIP gene, yielded pKTS 534. Following
deletion of the vector Xba I site by digestion with Xba I,
Klenow polymerase treatment, and religation (yielding pKTS
536), an Xba I linker was inserted into the unique Stu I site,
yielding pKTS 540. Next, a 2.3 kb Spe I fragment from pQ106
[23] containing the gpt and enhanced green fluorescent
protein (eGFP) cassette was inserted into the Xba I site of
pKTS 540, yielding pKTS 545 (Figure 1(a)).
Generation of the MIP deletion virus was performed as
described elsewhere [15, 16]. For generation of this recombi-
nant virus, plasmid pKTS 545 was cotransfected with viral
DNA into GPL cells, and selection was carried out using
mycophenolic acid and xanthine as previously described [23].
Following limiting dilution, eGFP-positive wells were iden-
tified and 6 rounds of plaque purification were performed
under selection, to ensure clonality of the recombinant viral
stock. A clonal eGFP-positive recombinant virus was purified
and designated as v545; this virus was used for subsequent
pathogenesis and vaccine studies.
2.2. Characterization of Recombinant Virus. For charac-
terization of recombinant virus, Southern blot analyses were
performed. Viral DNA purified from v545 and wild-type
(ATCC) GPCMV was subjected to restriction enzyme diges-
tion with Hind III and EcoR I, followed by agarose gel
electrophoresis. Following transfer to Nytran membranes,
DNA probes corresponding to the GPCMV-MIP gene [13] or
to the gpt/eGFP cassette were labeled with [32P] dCTP,
using a High Prime kit (BoehringerMannheim) according to
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Figure 1: Schematic representation of the GPCMV MIP gene and generation of recombinant virus. (a) Map of GPCMV genome. GPCMV
MIP (gp1 gene)maps to 2.3 kb EcoR I fragment near left genome terminus. Knockout of gp1was achieved by introduction of gpt/eGFP cassette
into a Stu I collapsed version of plasmid DNA. Following co-transfection of plasmid and viral DNA and gpt selection as described in text,
a clonal recombinant virus was obtained by limiting dilution. (b) Southern blot analysis of wild-type (ATCC 22122; left panel) and v545
(recombinant) DNA. Probing with pKTS107 probe revealed presence of restriction polymorphisms demonstrating predicted configuration
of recombinant virus. H, Hind III digest; E, EcoR I digest; X, Xba I digest. Molecular weight markers, lamba/Hind III ladder. (c) To further
characterize the genome structure of the v545 mutant, viral DNA was analyzed by PCR.The PCR was done using primer pairs cassette F1/R1
(upper panel) and cassette F2/R2 (lower panel) which, respectively, amplify 552 bp and 671 bp products in wild-type GPCMV and vAM403.
Insertion in v545 coupledwith deletion ofMIP gene results in overall shifts in bands to∼2.8-2.9 kb, as predicted. Subsequent sequence analysis
of gel-purified products confirmed predicted insertion and genome structure of v545 vaccine virus.
manufacturer’s specifications (Figure 1(b)). To further char-
acterize the genome structure of the v545 mutant, viral DNA
was analyzed by PCR. The PCR was done using primer
pair cassette F1/R1 and cassette F2/R2 which, respectively,
amplified 552 bp and 671 bp products in wild-type GPCMV.
Primer sequences were cassette F1, 5󸀠-GACCCTCTAACA-
TATCGGAG-3󸀠; cassette R1 5󸀠-AAGAACATGGCTGTC-
CGCTA-3󸀠; cassette F2 5󸀠-TTCTCTCACGTTGAGCGCAT-
3󸀠 cassette R2 5󸀠-CCTATCGATACGTGGATACG-3󸀠. The
PCR reaction was performed in a total volume of 50 𝜇l using
GoTaq long PCR Master Mix (Promega laboratories) and
1.0 𝜇M primers. The conditions for the PCR were initial
denaturation at 95∘C for 2min, followed by 95∘C for 30 s, 56∘C
for 30 s, 72∘C for 3min for a total of 35 cycles, and elongation
at 72∘C for 10min. The PCR product (9𝜇L) was subjected to
electrophoresis in a 0.7% agarose gel (Figure 1(c)).
Rescue virus was generated as previously described [24].
Briefly, 1 𝜇g of v545 DNA was cotransfected with 20𝜇g of
rescue plasmid (pKTS 107) onto GPL cells. Rescued, eGFP-
negative viral plaques were picked and subject to further
rounds of plaque purification by limiting dilution. Rescue
of GPCMV-MIP was confirmed by PCR and by restriction
profile analysis (data not shown).
One-step growth curve analyses were conducted to com-
pare wild-type (GPCMV ATCC, 22122), recombinant, and
rescued viruses. Clonal stocks were used to infect confluent
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Figure 2: One-step growth curve analysis of recombinant virus
v545. Wild-type (ATCC 22122), recombinant (v545) and rescuant
(v545R) viruseswere used to infect confluent cell culturemonolayers
at an m.o.i. of 0.5 pfu/cell. After absorption for 1 h at 37∘C, the cells
were washed with media and a zero time point was harvested. The
remainder of the sample was incubated at 37∘Cwith additional time
points taken at indicated times.The viral titer of each time point was
determined by plaque titration assay on GPL cells.
monolayers at an m.o.i. of 0.5 pfu/cell. After adsorption for
1 h at 37∘C, the cells were washed with media and a zero time
point was harvested. Additional time points were obtained
at 24, 48, 72, 96, 120, and 144 h after inoculation, and the
viral titer of cell culture supernatant obtained at each time
point was determined by plaque titration assay on GPL cells
(Figure 2).
2.3. Animal Studies of Recombinant Viruses following Sys-
temic and Footpad Inoculation. Hartley guinea pigs were
purchased from Elm Hill Laboratories (Chelmsford, MA,
USA). Strain 2 guinea pigs were maintained in the vivarium
of the University of Minnesota Medical School. Animals
were housed under conditions approved by the American
Association of Accreditation of Laboratory Animal Care, in
accordance with and following approval from the Institu-
tional Animal Care and Use Committee at the University of
Minnesota.
The v545 recombinant had been previously demonstrated
to have an altered pathogenesis in guinea pigs compared to
a similar recombinant, vAM403 (which has the eGFP/gpt
cassette inserted into a noncoding region of the GPCMV
genome), following intracochlear inoculation [15, 16]. To fur-
ther characterize the impact of deletion of the GPCMVMIP
on the in vivo pathogenesis of infection, viremia (Figure 3)
and footpad inoculation studies (Figure 4) were conducted in
nonpregnant, weanling animals. For viremia studies, young
strain 2 guinea pigs (𝑛 = 6/group) were inoculated by
intraperitoneal route with 1 × 107 pfu of either vAM403 or
v545 virus (Figure 3(a)). The vAM403 virus was used as
a control, rather than the v545 rescue virus, since it (like
vAM403) expressed eGFP and also had a similar insertion
into the viral genome. Animals were then monitored every
other day for nine days following infection for weight loss or
gain. On day 10, animals were bled for analysis of systemic
viral load by PCR (Figure 3(b)). To evaluate inflammation at
a local site of primary infection, additional adult animals (𝑛 =
6) were inoculated in the footpad with 5 × 104 pfu of either
vAM403 virus or v545 virus. For each group, media alone
was inoculated into the contralateral paw. Foot thickness was
measured using a digital caliper as described elsewhere [25],
daily for 6 days (Figure 4(a)), in a coded, blinded fashion. On
day 7, animals were sacrificed and tissues harvested, formalin
fixed, and decalcified; after embedding in paraffin, 5 𝜇m
sections were cut and stained with hematoxylin and eosin
to evaluate for histopathology and evidence of inflammation
(Figure 4(b)).
2.4. Vaccine/Challenge Studies. Hartley strain guinea pigs
were purchased, as previously noted, from Elm Hill lab-
oratories. All animals (𝑛 = 15/group) were determined
to be GPCMV seronegative prior to vaccination by ELISA.
Animals were immunized twice, with an interval of 3 weeks
between doses, with 5 × 104 pfu of v545 vaccine, by subcu-
taneous route in a total volume of 1mL. Control animals
received an identical volume of phosphate-buffered saline.
Bleeds were performed once a week for 6 weeks on all guinea
pigs following vaccination for both quantitative PCR analysis
of viral load and for serumanalysis. After 6weeks, bleedswere
performed every other week until the conclusion of the study.
Three weeks following the second immunization, ani-
mals were mated with seronegative male Hartley guinea
pigs. Mating persisted until abdominal palpitation confirmed
pregnancy. Approximately 4 weeks before delivery, pregnant
dams were challenged with a subcutaneous injection of 1
× 106 pfu/mL of a virulent, salivary gland-derived GPCMV
workpool. Bleeds were performed in infected dams on days
5, 10, and 15 after challenge for quantitative PCR analysis
of viral load and for plasma analysis. Upon delivery, pups
were weighed and live-born pups sacrificed within 96 hours
of birth and blood obtained for quantitative PCR analysis
of viral load. Lung, liver, spleen, and placenta were also
extracted for evaluation of organ pathology and quantitative
PCR analysis of viral load.
2.5. Immunologic and Virologic Studies. ELISA analysis (Fig-
ure 5(a)) was performed as previously described [26], with
titer determined by limiting dilution assay (initial dilution,
1 : 80). A positive result was determined by calculating
the reciprocal of the highest dilution that produced an
absorbance of at least 0.1 and twice the absorbance observed
using a negative control antigen. Plates were read at a wave-
length of 450 nm using the SpectraMax M2 Spectropho-
tometer (Molecular Devices) and the ScanMax Pro program.
Western blot analysis was performed on serumcollected from
a subset of guinea pigs from the vaccine and control groups
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Figure 3: The v545 virus is attenuated in strain 2 guinea pigs. (a) Weight loss and DNAemia profiles were compared following inoculation
of young, nonpregnant guinea pigs with v545 and control vAM403 virus. Animals inoculated with v545 gained weight throughout this
postinoculation time period (mean weight gain at day 9, 40 grams) compared to animals infected with vAM403 (weight loss of 5 grams;
𝑃 < 0.01). (b) Animals challenged with v545 virus demonstrated reduced DNAemia measured at day 10 (mean viral load, 2.5 log
10
genomes/mL versus 3.0 log
10
genomes/mL in vAM403 group; 𝑃 < 0.05).
(Figure 5(b)). Serum was collected before vaccination from
each experimental group (preimmune) and at 2, 3, 5, 7, 9 and
11 weeks, as outlined schematically in Figure 5. For western
blot studies, virus particles were subjected to SDS-PAGE
and were then transferred onto nitrocellulose membranes by
electroblotting. Membranes were blocked using membrane
blocking agent (GEHealthcare) resuspended in Tris-buffered
saline plus 0.5% Tween (TBST) and then incubated for 3.5
hours with the aforementioned collected sera (1 : 800). Along
with serum samples obtained from the above time points, a
gB-specific polyclonal rabbit antiserum (1 : 500) and a high-
titer guinea pig polyclonal antiserum (1 : 10,000) were used as
controls [27]. After washing in TBST, blots were incubated
with either a horseradish peroxidase-conjugated rabbit anti-
guinea pig antiserum (1 : 10,000; Santa Cruz Biotechnology)
or a horseradish peroxidase-conjugated donkey anti-rabbit
antiserum (1 : 10,000; Santa Cruz Biotechnology) for 2 hours
at 27∘C. Antibody binding was then detected using the ECL
Western Blot Detection Kit (GE Healthcare), followed by
autoradiography (Hyblot CL; Denville Scientific, Inc.).
For detection of viremia following intraperitoneal inoc-
ulation of strain 2 guinea pigs (Figure 3), a quantitative,
competitive PCR assay was employed, as described else-
where [28]. For congenital transmission comparisons and
for assessment of viral load in pregnant animals, real-time
PCRwas performed.DNAwas extracted from200 𝜇L citrated
whole blood using the MagNA Pure LC System (Roche)
or 150 𝜇L of 10% tissue homogenate using the QIAxtractor
(QIAGEN). The GPCMV gB-specific primer pair LCF1 (5󸀠-
CTTCGTGGTTGAACGGG-3󸀠) and LCR1 (5󸀠-GTAGTC-
GAAAGGACGTTGC-3󸀠)were utilized for the real-timePCR
assay. The PCR reaction was performed in a 20𝜇L volume
reaction as specified by the LightCycler FastStart DNA Mas-
ter HybProbe reaction mix (Roche Diagnostics). GPCMV
gB-specific hybridization probes were used for detection
(LCPG 5󸀠-TGGTGACCTTCGTTACCAATCCGTTTGGA-
F; LCPR 5󸀠R640-CTTCGTGGTGTTCCTGTTCTGCGT-P).
PCRwas performed using the LightCycler 480 real-time PCR
System (Roche) under the following conditions: initial denat-
uration at 95∘C for 10min, followed by 95∘C for 10 s, 54∘C for
15 s, 72∘C for 15 s for a total of 50 cycles, followed by melting
curve analysis at 95∘C for 1min and 45∘C for 1min and ending
at 85∘C, and then a final hold step at 40∘C.Data were analyzed
with the Light-Cycler Data Analysis Software (version 1.0;
Roche) using standard curves generated using serial dilutions
of plasmid and viral DNA at known concentrations. The
magnitude of DNAemia was expressed as the total number of
genome copies per mL of blood or total number of genome
copies per 𝜇g of tissue.
2.6. Statistical Comparisons. Antibody titers were compared
using the paired Student’s 𝑡-test. Parametric variables were
compared by ANOVA. Nonparametric variables were com-
pared using theMann-Whitney𝑈 test or the pairedWilcoxon
test.The proportion of live-born pups, infected pups, and the
birth weights were compared/calculated using generalized
linear mixed models (GLMM) to account for within-litter
variability [29]. Statistics were analyzed using the Prism 5.0
software package (GraphPad Software, San Diego) and R
v2.13.0.
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Figure 4: The v545 virus is attenuated in a footpad inoculation model. Using calipers, differences between wild-type (vAM403) and CK
deletion virus (v545) were noted following footpad inoculation, beginning at day 3 and progressing through day 6. The level of swelling
produced by the vAM403 virus was noted to be ∼20% above preinoculation levels, compared to the results obtained with v545 (𝑃 < 0.01). All
swelling resulted from the effects of virus in the inoculum because inoculation of an identical volume of tissue culture medium alone failed to
elicit any response (controls, Figure 4(a)). Feet were collected from sacrificed guinea pigs at day 6 after inoculation, and midline longitudinal
sections were prepared. Examination by light microscopy at both low and high power (×10 and ×60; Figure 4(b)) revealed substantially larger
amounts of both cellularity and edema in animals inoculated with vAM403 virus (Figure 4(b), right panel), containing the GPCMV MIP
ORF, than in v545 virus-inoculated animals (Figure 4(b), middle panel) or in media-inoculated control (Figure 4(b), left panel).
3. Results
3.1. MIP Gene Deletion Does Not Modify Viral Replication in
Cell Culture but Attenuates GPCMV Infection and Dissemi-
nation in Guinea Pigs. The GPCMV MIP gene was deleted
from the viral genome using a well-established model of
selection for recombinant virus, gpt selection. The genome
structure of the recombinant virus, v545, was verified by
Southern blot study (Figure 1(b)). A GPCMV-MIP-specific
probe was found to hybridize with viral DNA purified
from GPCMV (ATCC) DNA, but not DNA purified from
v545. However, a gpt/eGFP-specific probe was found to
hybridize withDNApurified from v545, but not ATCCDNA.
Moreover, insertion of this cassette into the GPCMV genome
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Figure 5: Immunogenicity of v545 attenuated vaccine. (a) ELISA profile following vaccination. Animals were immunized twice, with an
interval of 3 weeks between doses, with 5 × 104 pfu of v545 vaccine, by subcutaneous route of inoculation. Control animals received an
identical volume of phosphate-buffered saline. Bleeds were performed at regularly intervals, as described in the text, on all guinea pigs
following vaccination for serum ELISA analysis. Selected sera were also used in western blot assay as indicated in panel (b). Data shown
represents the mean ± SD reciprocal ELISA titer for the vaccine group at each time point. (b) Representative profile of response from
vaccinated dam using viral particles in western assay. Marker lane is indicated (M). Lanes 1–4, preimmune sera and sera from weeks 2, 5,
and 11 following vaccine. Lane 5, western profile of high-titer anti-GPCMV antisera. Lane 6, western blot with anti-GPCMV gB polyclonal
antibody. Immunized animals demonstrate anti-gB antibodies (arrowhead) in addition to antibody to other GPCMV polypeptides. Initial
response targets virion proteins of ∼35 and 45 kDa noted at 2 weeks after vaccination, followed by responses to gB and a ∼70 kDa protein
following second immunization at 5-week time point. Last serological responses to appear target proteins of ∼22 kDa, noted at 11-week time
point.
generated novel EcoR I restriction polymorphisms, which
could be demonstrated both with GPCMV-specific probes
and gpt/eGFP-specific probes. To confirm the Southern blot
observations, and also to confirm that potential adjacent
ORFs were not modified, PCR was performed (Figure 1(c)),
followed by sequence analysis. This confirmed the predicted
orientation and insertion into the GPCMV genome. During
the course of these studies, it was noted by Inoue and
colleagues that two types of strains of GPCMV are present
in virus stocks obtained from ATCC: GPCMV/full, and
GPCMV/del, containing a 1.6 kb deletion in a locus encoding
the GPCMV homologs of the HCMV UL128-131 complex
[30]. We noted by PCR that both v545 and vAM403 had a
GPCMV/del genome variant, presumably due to prolonged
passage of ATCC virus in fibroblast cells (data not shown).
We conclude based on these analyses that v545 has a targeted
deletion of GPCMV MIP, but otherwise an intact genome
structure, compared to the GPCMV/del ATCC variant.
Replication kinetics of v545 in cell culture were compared
to that of wild-type (ATCC) GPCMV and another eGFP-
tagged recombinant. In these experiments, one-step growth
curve analyseswere performedwith v545;ATCCvirus; a v545
rescuant; and a previously described recombinant GPCMV
with the gpt/eGFP cassette inserted in a noncoding region of
the viral genome, vAM403 [23]. These comparisons revealed
that deletion of the GPCMV MIP had no impact on the
replication of GPCMV in cell culture (Figure 2).
Previously, we reported on the reduced pathogenesis
of the v545 mutant virus in a direct inoculation model
of cochlear pathogenesis and hearing loss [15, 16]. It was
therefore of interest to further examine the impact of deletion
of the GPCMV MIP ORF on the pathogenesis of infec-
tion. Weight loss and DNAemia were compared following
inoculation of young, nonpregnant guinea pigs with v545
(MIP deletion virus; Figure 3). Animals inoculated with
v545 gained weight throughout this postinoculation time
period (mean weight gain at day 9, 40 grams) compared
to animals infected with vAM403 (weight loss of 5 grams;
𝑃 < 0.01). In addition, animals challenged with v545 virus
demonstrated a significant reduction in the magnitude of
DNAemia measured at day 10 (mean viral load, 2.5 log
10
genomes/mL versus 3.0 log
10
genomes/mL in vAM403 group;
𝑃 < 0.05).
To further characterize the biology of wild-type and
deletion virus in guinea pigs, a footpad inoculation model
was employed, as previously described for analyses of other
rodent CMVs [25, 31]. Using this model, differences between
wild-type (vAM403) andCKdeletion virus (v545)were noted
beginning at day 3, and progressing through day 6, when
the level of swelling produced by the vAM403 virus was
noted to be ∼20% above preinoculation levels, compared to
the results obtained with v545. All swelling resulted from
the effects of virus in the inoculum because inoculation of
an identical volume of tissue culture medium alone failed
to elicit any response (controls, Figure 4(a)). In order to
further investigate cellular infiltrates in response to GPCMV
MIP, feet were collected from sacrificed guinea pigs at day
6 after inoculation, and midline longitudinal sections were
prepared from formalin-fixed, paraffin-embedded blocks.
Examination by light microscopy at both low and high
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power (×10 and×60; Figure 4(b)) revealed substantially larger
amounts of both cellularity and edema in animals inoculated
with vAM403 virus, containing the GPCMVMIP ORF, than
in v545 virus-inoculated animals. All areas of inoculated feet
(dorsal, internal, and ventral) appeared less inflamed, with
differences in foot thickness measured grossly using calipers
correlating with the histopathological findings. At low power,
the presence of theGPCMVMIP gene correlatedwith amuch
more intense local inflammatory response, and differences in
cellularity with an increased mononuclear cell infiltrate were
readily discernable.
3.2. Immunogenicity and Safety of v545 Employed as an Atten-
uated Vaccine Candidate. Based on its favorable attenuation
profile in nonpregnant animals, we studied the MIP deletion
virus as a candidate live, attenuated vaccine. A two-dose
immunization series (5 × 104 pfu) was administered subcu-
taneously to 15 young, GPCMV-seronegative guinea pigs, at
three-week intervals. A similar group of 15 guinea pigs were
immunized with phosphate-buffered saline (negative control
group). Analysis of ELISA response indicated that only 2/15
animals (13%) demonstrated a response within three weeks
of the first vaccination; however, within two weeks of the
second vaccination, all animals were GPCMV-seropositive
(mean reciprocal ELISA titer, 616; Figure 5(a)). Western
blotting was performed in order to further characterize the
humoral response following vaccination with v545 virus.
These analyses demonstrated (Figure 5(b)) similar patterns
of response to those noted using a high-titer polyclonal, anti-
GPCMV antisera obtained from an animal infected with
wild-type virus.
3.3. Maternal and Fetal Outcomes in a Pregnancy/Challenge
Study Using v545 Vaccine. The effect of the 545 attenuated
virus vaccine on pup mortality due to disseminated GPCMV
in Hartley guinea pigs (two doses of vaccine) was analyzed.
All 15 dams in the vaccine group completed pregnancy. In the
control group, 13 animals became pregnant and had evaluable
pregnancy outcomes. In the control group, pupmortality was
35/50 (70%). In contrast, pupmortality in litters born to v545-
vaccinated dams was 8/52 (14%; 𝑃 < 0.0001 compared to
vaccine group). Mean birth weights of the pups delivered in
each group were also compared. Among pups born in the
control group, live-born pups (𝑛 = 15) had a mean weight of
87.1 g (4.25 SE), while dead pups (𝑛 = 35) had a mean weight
of 62.2 g (8.70 SE). In contrast, in the v545 vaccine group, live-
born pups (𝑛 = 44) had an average weight of 97.4 g (2.16 SE),
while stillborn pups had a mean weight of 107.6 g (3.97 SE)
(𝑛 = 7; one stillborn pup was not weighed). Overall, mean
pup weight was 71.2 g (6.13, SE) in the control group, and
98.7 g (1.86, SE) in the vaccine group (𝑃 < 0.0001; Table 1).
Of 15 litters born to vaccinated dams, 3 (5%) had at least one
dead pup, while 12/13 litters born to dams in the control group
had at least one dead pup (𝑃 < 0.001 compared to control
group, Fisher’s exact test).
The v545 vaccine had a substantial impact on maternal
viremia and congenital GPCMV infection. All maternal
blood samples taken before SG virus challenge were negative
Table 1: Pregnancy outcomes (pup mortality) after challenge with
SG-passaged GPCMV in vaccinated and control dams.
Litter Dead/total
Control
1 3/3
2 3/4
3 4/4
4 2/5
5 0/2
6 4/4
7 3/3
8 1/4
9 2/3
10 3/4
11 5/5
12 3/6
13 2/3
Total 35/50 (70%)
V545 vaccine
1 0/3
2 0/3
3 0/4
4 5/5
5 0/4
6 0/3
7 0/4
8 1/1
9 0/4
10 1/5
11 0/4
12 0/3
13 0/2
14 1/4
15 0/3
Total 8/52 (15%)
by qPCR. Following SGvirus challenge, in control dams, 12/13
demonstrated DNAemia at day 5 postinfection, with a mean
viral load of 4.4 ± 0.4 log
10
genomes/mL. In contrast, only
1 of 15 dams immunized with v545 vaccine demonstrated
DNAemia on day 5 after salivary gland virus challenge, with
the sole positive sample having a viral concentration of 3.5
log
10
genomes/mL. PCR of DNA purified from pup organs
demonstrated congenital GPCMV infection in 24/49 liver
homogenates; 19/46 spleen homogenates; and 28/46 lung
homogenates. One dead pup in this group was homogenized
en bloc (PCR negative). Overall, 35/50 pups (10/15 among
live-born pups, and 25/35 among dead pups) in the control
group had congenital infection as evidenced by at least one
positive tissue PCR (70% overall congenital infection rate)
(Table 2). A total of twenty placentas could be retrieved from
this group, and all were positive for GPCMV DNA by PCR.
In the v545 vaccine group, PCR of DNA purified from pup
organs demonstrated congenital GPCMV infection in 6/52
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Table 2: Summary of litters and presence or absence of congenital
GPCMV infection in vaccine and control groups.
Litter PCR positives
Control
1 3/3
2 4/4
3 4/4
4 4/5
5 2/2
6 2/4
7 3/3
8 1/4
9 2/3
10 4/4
11 1/5
12 4/6
13 1/3
Total 35/50 (70%)
V545 vaccine
1 0/3
2 0/3
3 1/4
4 2/5
5 0/4
6 0/3
7 0/4
8 0/1
9 1/4
10 0/5
11 0/4
12 0/3
13 1/2
14 1/4
15 3/3
Total 9/52 (17%)
liver homogenates; 2/52 spleen homogenates; and 5/52 lung
homogenates. Overall, congenital GPCMV transmission was
identified in 9/52 pups (7/44 live-born pups and 2/8 dead
pups) for an overall 11% congenital infection rate (𝑃 < 0.0001
compared to control). A total of 8/34 retrieved placentas were
positive for GPCMV DNA (24%; 𝑃 < 0.0001 versus control
group). In PCR-positive placentas from the vaccine group,
the mean viral load was 2.2 ± 0.3 log
10
genomes/mg DNA,
compared to 5.7 ± 1.0 log
10
genomes/mg in placentas from
control (unvaccinated) animals (𝑃 < 0.0001, Mann-Whitney
test).
4. Discussion
In this study, a live, attenuated CMV vaccine was generated,
based on deletion of a functional CCCK gene from the
GPCMV genome [13, 14], using a gpt-based mutagenesis
approach. This recombinant virus was highly attenuated for
replication in guinea pigs, both in terms of its capacity to
elicit systemic infection as well as in its ability to elicit
localized inflammation andhistopathology following footpad
inoculation. In spite of this attenuation, the virus was capable,
when administered as a vaccine to nonpregnant female
guinea pigs, of eliciting high-titer ELISA antibody responses.
Unfortunately, neutralizing titers could not be performed,
due to a limitation in available serum, but the magnitude
of the ELISA response was comparable to that observed in
natural infection, and the ELISA titer has correlated with
the neutralizing response in past studies in this model [32].
Vaccinated animals, following establishment of pregnancy,
were protected against DNAemia after virulent salivary-
gland virus challenge, and their pups were protected both
against GPCMV-associatedmortality andGPCMV infection.
These observations provide further evidence both for a
role of virally encoded immune modulation genes in the
pathogenesis of infection in vivo, as well as for the highly
attenuating effect of genetic manipulations designed to delete
such genes in the design of live, attenuated vaccines.
The presence of virally encoded mimics of host CCCK
genes has been noted for other rodent CMVs. The most
extensively studied of these CKs has been the CCCK encoded
by the MCMVMCK-1 gene. Mice infected with recombinant
MCMVs with mutations in this gene developed less inflam-
mation at the site of inoculation, demonstrated reduced
secondary viremia, and had lower viral titers in the salivary
glands [25, 33]. Rat CMV (RCMV) encodes a CCCK with
similarity to the MCK-1 gene product, and rats infected with
deletion mutants had reduced viral loads in the spleen and
salivary glands, as well as reduced swelling and macrophage
infiltration at the site of virus inoculation [31]. Previous study
of theGPCMVCCCK,GPCMV-MIP [13], demonstrated that
a mutant deleted of the CK coding sequences was attenuated
for its ability to elicit inflammation and hearing loss following
direct intracochlear inoculation in guinea pigs [15, 16]. In
additional comparisons of the CK deletion virus, v545, with
a virus containing the intact CK gene, vAM403, we observed
both reduced DNAemia and weight loss following systemic
viral challenge (Figure 3) and reduced footpad swelling
and histopathology following localized infection (Figure 4)
with the deletion virus compared to the CK-intact virus.
This suggests that, as with other rodent CMVs, there is an
important role for this CK in the pathogenesis of GPCMV
infection in vivo.
The concept of using molecular genetic approaches to
engineer recombinant CMVs, toward the goal of creating
less pathogenic and/or more immunogenic live, attenuated
vaccine candidates, has been previously described for both
GPCMV [26] and MCMV [19–21, 34]. The targeting of
immune modulation genes in vaccine design is of particular
appeal given that there are substantial concerns about the
potential long-term risks of live, attenuated HCMV vac-
cines, which could theoretically include latency, oncogenesis,
autoimmune disease, and atherosclerosis [35]. In a previous
report, the deletion of 3 GPCMV genes with homology to
host MHC-I genes, using a bacterial artificial chromosome
recombinatorial approach, resulted in a vaccine virus that
was rapidly cleared in animals but was nonetheless highly
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immunogenic and protective in the congenital infection
model. The mechanism of immune evasion mediated by the
class I gene family is currently under investigation but may
be related to impairment of NK cell clearance. In the present
study, gpt mutagenesis was chosen to generate recombinant
virus, since the location of the GPCMV MIP gene was near
the site of the BAC insertion in the viral genome in the
BAC construct [23], making additional insertions and mod-
ifications in this region more challenging. Presumably, the
mechanism of attenuation of the v545 (CCCK deletion) virus
described in this study stems from its decreased propensity to
mediate an acute inflammatory response. Since the ability of
virus to disseminate and establish latency in the salivary gland
may be impaired by deletion of viral CKs [25, 31], vaccine
strains generated with such targeted deletions may have an
improved safety profile.
One limitation of the analyses of theGPCMVMIPknock-
out and wild-type viruses performed in these studies is that
the deletion of the MIP gene was superimposed on a tissue
culture-derived (ATCC) viral stock of GPCMV. Subsequent
to the initiation of our studies, it was demonstrated that the
ATCC stock of GPCMV has a 1.6 kb deletion that removes
several GPCMV genes, including GP129, GP131, and GP133
[30, 36]. These genes encode homologs to HCMV UL128,
UL130, and UL131, respectively, proteins which play a critical
role in formation of the pentameric complex (PC), along
with gpUL75 [gH] and gpUL115 [gL], essential for HCMV
for the endocytic entry pathway required for infection of
endothelial and epithelial cells [37–40]. Recently it has been
shown that the GPCMV homologs similarly encode a PC
that plays a role in virus entry [41]. Viruses lacking this
1.6 kb region are impaired for replication in vivo following
experimental challenge of guinea pigs compared to those that
retain these gene products [30, 36]. Since our recombinant
viruses were generated against an ATCC background lacking
this 1.6 kb region [23, 42], the deletion of GPCMV MIP
in the recombinant virus, v545, is therefore superimposed
upon a virus already lacking in genes that play an impor-
tant role in the pathogenesis of infection. However, it is
clear that the deletion of GPCMV MIP confers additional
attenuation, above that already conferred by deletion of the
1.6 kb pathogenicity locus. Importantly, the attenuation of
v545 pathogenicity reported in this and other studies [15,
16] was based upon comparisons to vAM403 virus [23], a
GPCMV recombinant that is also lacking in this 1.6 kb locus.
The vAM403 virus, also engendered by gpt mutagenesis, is
similar to v545, except that (1) it retains the GPCMV MIP
gene; (2) it has the gpt/eGFP cassette inserted in a noncoding
region of the GPMCV genome.Therefore, the clear pattern of
attenuation conferred by deletion of the GPCMV MIP gene
in the v545 virus, compared to vAM403, provides reassurance
regarding the role of this CCCK in pathogenesis. Efforts are in
progress to reengineer theMIP deletion against the backdrop
of a full-length GPCMV genome, using bacterial artificial
chromosome-based approaches [42].
It was of interest to note that the v545 vaccine was
capable of eliciting a highly protective immune response,
in spite of the fact that it lacks the GP129-133 PC proteins.
This observation suggests that the PC is not required for
a successful CMV vaccine. Recently, it was shown that, in
the absence of the rhesus CMV genes Rh157.5, Rh157.4, and
Rh157.6 (homologs of HCMV UL128, 130, and 131), CD8+
T cells are generated against unusual, diverse, and highly
“promiscuous” epitopes [43]. The ability of UL128, 130, and
131 proteins to divert CD8+ T cell targeting away from
unconventional epitopes could suggest that deletion of these
genes might confer a more diverse T cell response to a
CMV vaccine. If similar mechanisms are at play in GPCMV,
this could contribute to the efficacy of a live, attenuated
vaccine with a deletion in this region of the genome, the
lack of an antibody response to the PC notwithstanding.
Additional studies of recombinant GPCMVs deleted of key
immune evasion and/or pathogenesis genesmay shed light on
attractive live, attenuated vaccine strategies for consideration
for future development in human clinical trials.
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